Recommendation made by the extraordinary PBAC meeting - March 2006

PDF Printable version this page (PDF 19 KB)

Recommendation made by the Pharmaceutical Benefits Advisory Committee (PBAC) at an extraordinary March 2006 Meeting relating to the listing of Insulin glargine on the Pharmaceutical Benefits Scheme (PBS)

Table containing positive recommendations for Insulin Glargine from March 2006 Extraordinary Meeting

Drug and Form	Drug Use and Type	Listing Requested by Sponsor	PBAC Recommendation
Insulin glargine, injection, 100 units per mL, 10 mL vials and 3 mL x 5 cartridges, Lantus® Sanofi-Aventis Group Major submission	Treatment for diabetes	Unrestricted listing	The PBAC recommended the listing of insulin glargine as an unrestricted benefit on the basis that the clinical benefit over NPH insulin (improvement in hypoglycaemic event rates) in a population which cannot be defined effectively, but which is likely to include those with a high level of need, was cost-effective at the new price proposed.
		Sponsor’s comments	Sanofi-aventis is pleased that we have been able to reach agreement with the PBAC. The efforts of both PBAC and sanofi-aventis have been in good faith and we look forward to the positive recommendation of the PBAC being accepted by the Government in the near future.